Skip to Main Content

Author Details

Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
1981
263
85
PMIDPaper TitleJournal TitlePublished Year
36413141Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.Cancer Res2023
37663929Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.Cancer Res Commun2023
37139568Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals.Am J Epidemiol2023
36622276WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth.Cancer Res2023
36877164LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Cancer Res2023
35333400Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.Cancer2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
35523889Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.Cancer Immunol Immunother2022
35254710Immune mechanisms behind prostate cancer in men of African ancestry: A review.Prostate2022
35131873Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer.Cancer Res2022
35121110Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.Mol Ther2022
35031563Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.Proc Natl Acad Sci U S A2022
35201849A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.JCO Precis Oncol2022
35082166Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.Mol Cancer Res2022
33037017Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.Clin Cancer Res2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
35008216Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.Cancers (Basel)2021
34911936Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.Nat Commun2021
34439209Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.Cancers (Basel)2021
34407973Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Clin Cancer Res2021
34568716Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors.JCO Precis Oncol2021
34168052A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Clin Cancer Res2021
34256096Androgen receptor splice variant 7 functions independently of the full length receptor in prostate cancer cells.Cancer Lett2021
32127357<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer.Cancer Res2020
32679108Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.Cancer Cell2020
32868907Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.Nat Genet2020
32478682Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.J Clin Invest2020
32484436MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.Elife2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
31676563Androgen Receptor Interaction with Mediator Complex Is Enhanced in Castration-Resistant Prostate Cancer by CDK7 Phosphorylation of MED1.Cancer Discov2019
30181386Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31302152VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells.Cell Syst2019
31444154ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.Cancer Res2019
30893145Targeting the androgen receptor and overcoming resistance in prostate cancer.Curr Opin Oncol2019
30932413Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis.Exp Oncol2019
30295334Characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident.Am J Hematol2019
29258679Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Eur Urol2018
30242112Downregulation of <i>Dipeptidyl Peptidase 4</i> Accelerates Progression to Castration-Resistant Prostate Cancer.Cancer Res2018
30217568Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer.Cancer Lett2018
30101540Addressing Cancer Chemotherapeutic Toxicity, Resistance, and Heterogeneity: Novel Theranostic Use of DNA-Encoded Small Molecule Libraries.Bioessays2018
30021909Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.Clin Cancer Res2018
29930797Calcium signaling: an underlying link between cardiac disease and carcinogenesis.Cell Biosci2018
30012673BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.Cancer Res2018
29921690Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.Cancer Res2018
30537509Initiation and Evolution of Early Onset Prostate Cancer.Cancer Cell2018
28062857Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.Nucleic Acids Res2017
32913968Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.JCO Precis Oncol2017
28414609Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.J Clin Oncol2017
28139868Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.Breast J2017
28389510Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.Clin Cancer Res2017
  • 1 - 50 of 263

Recommended Authors

Oregon National Primate Research Center
Career Start Year 2010
Number of shared co-authors 11
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 13
University of British Columbia
Career Start Year 2004
Number of shared co-authors 26
University of Cambridge
Career Start Year 2003
Number of shared co-authors 8
University of California los angeles
Career Start Year 2003
Number of shared co-authors 2
University of British Columbia
Career Start Year 2002
Number of shared co-authors 55
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 27
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 39
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 1
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 30
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 2
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 24
David Geffen School of Medicine, University of California los angeles
Career Start Year 1995
Number of shared co-authors 60
The Francis Crick Institute
Career Start Year 1994
Number of shared co-authors 2
Georgetown University
Career Start Year 1993
Number of shared co-authors 3
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 16
University of Texas Health San Antonio
Career Start Year 1990
Number of shared co-authors 5
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 9
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 1
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 27
University of Utah
Career Start Year 1986
Number of shared co-authors 41
Eastern Virginia Medical School
Career Start Year 1985
Number of shared co-authors 13
Karolinska Institute
Career Start Year 1984
Number of shared co-authors 7
Queen's University
Career Start Year 1982
Number of shared co-authors 21
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 0
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 14
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 10
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 21
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 2

Collaborators

Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 35
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 32
Memorial Sloan Kettering Cancer Center
Co-authored papers 26
Fred Hutchinson Cancer Center
Co-authored papers 22
University of Washington
Co-authored papers 20
National Cancer Institute
Co-authored papers 19
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 17
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 16
Co-authored papers 15
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 14
Weill Medical College of Cornell University
Co-authored papers 13
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 12
University of Washington School of Medicine
Co-authored papers 11
National Cancer Institute
Co-authored papers 10
University of Washington
Co-authored papers 9
University of Washington School of Medicine
Co-authored papers 9
Co-authored papers 9
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 7
Co-authored papers 7
Dana-Farber Cancer Institute
Co-authored papers 7
Co-authored papers 7
University of Bern
Co-authored papers 6
Co-authored papers 6
The Institute for Cancer Research
Co-authored papers 6
Tulane University School of Medicine
Co-authored papers 6
Co-authored papers 5
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Co-authored papers 4
University of Washington
Co-authored papers 4
Co-authored papers 4